Rob Dillard

DocwireNews

A new study found that dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of therapies used to control blood sugar levels in adults with type 2 diabetes, may reduce the risk of melanoma but not nonmelanoma skin cancer. The results were presented at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, California.
Researchers sought to determine whether DPP-4 inhibitors are linked to the incidence of melanoma and nonmelanoma skin cancer compared with sulfonylureas. Using the Clinical Practice Research Datalink, they assessed 96,739 DPP-4 inhibitor users and 209,341 sulfonylurea users for melanoma, and 96,411 DPP-4 inhibitor users and 208,626 sulfonylurea users for nonmelanoma skin cancer.
According to the results, DPP-4 inhibitors were associated with a 23% decreased risk of melanoma compared with sulfonylureas (49.7 vs 65.3 per 100,000 person-years, respectively; hazard ratio [HR], 0.77; 95% CI, 0.61-0.96). However, DPP-4 inhibitors were not associated with a reduced incidence of nonmelanoma skin cancer compared with sulfonylureas (448.1 vs 426.1 per 100,000 person-years, respectively; HR, 1.06; 95% CI, 0.98-1.15). “In this large, population-based cohort study, DPP-4 inhibitors were associated with a reduced risk of melanoma, but not nonmelanoma skin cancer, compared with sulfonylureas,” the researchers concluded.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Adults With Type 2 Diabetes Taking DPP-4 Inhibitors Have a Lower Risk of Melanoma

American Diabetes Association's 83rd Scientific Sessions

ADA 2023

DPP-4 inhibitors, used to control blood sugar levels in adults with type 2 diabetes, may reduce the risk of melanoma. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe